Table 2 Monitoring of laboratory parameters in 17 patients with leprosy enrolled in the safety study
From: Evaluation of safety tool for ambulatory leprosy patients at risk of adverse outcome
Laboratory parameter | Pre-Implementation of safety tool | Post-Implementation of safety tool | ||
|---|---|---|---|---|
Number | % | Number | % | |
Dapsone-induced hemolysis > 10 g/L | 1/3 | 33.3 | 5/9 | 56.0 |
Elevated methemoglobin level | 1/2 | 50.0 | 8/9 | 89.0 |
Glycemic monitoring after prednisone initiation | 1/1 | 100.0 | 9/9 | 100.0 |
Steroid-induced hyperglycemia | 0 | 0 | 4/9 | 44.4 |
Hepatic transaminase monitoring in those on Rifampin | 6/8 | 75.0 | 9/9 | 100.0 |
Elevation of hepatic transaminases in those on Rifampin | 0 | 0 | 2/9 | 22.2 |